Eli Lilly and Company (NYSE:LLY) is one of the Top 10 Stocks Wall Street is Buzzing About These Days. Talking about Morgan ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral ...

Eli Lilly (LLY) recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its Alzheimer's drug donanemab, underscoring the company's advancements in a ...

Eli Lilly's stock isn't cheap The company's stock trades at a hefty 39 times forward earnings. That's very high for a pharma company and more than twice its main GLP-1 competitor, Novo Nordisk .

Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance Eli Lilly sees FY24 EPS $12.20-$12.70, consensus $12.43 Eli Lilly reports Q4 EPS $2.49, consensus $2.19 ...

Eli Lilly (NYSE:LLY) is scheduled to release its earnings report on Thursday, May 1, 2025. For event-driven traders, historical stock performance following earnings announcements may offer ...

Through an analysis of Eli Lilly, we can infer the following trends: At 86.87, the stock's Price to Earnings ratio significantly exceeds the industry average by 3.52x, suggesting a premium ...

Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its shares.